Palmitoyl Tripeptide-1

This cosmetic ingredient combines glycine–histidine–lysine with a palmitic-acid chain. The peptide portion is a collagen-derived fragment, while the fatty acid is intended to aid skin delivery. Sederma supplies it as one of the two peptides in Matrixyl 3000; it should not be confused with copper-bound GHK-Cu or with original Matrixyl’s pentapeptide.

As a matrikine, it is proposed to signal dermal fibroblasts to produce matrix proteins. Cell-model and supplier findings describe increased type I and III collagen and fibronectin. The palmitic-acid group is included for topical delivery. These findings motivate firmer-looking skin and fine-line claims, but do not independently demonstrate clinical reconstruction of collagen.

Palmitoyl tripeptide-1 is a cosmetic, not an FDA-approved medicine. Ordinary cosmetic ingredients do not require drug-style preapproval. Appearance and feel claims differ from claims to rebuild bodily collagen, which may make a product a drug.

Age-appearance serums and creams commonly pair it with palmitoyl tetrapeptide-7 as Matrixyl 3000. Products aim for a firmer, plumper look and less visible fine lines or wrinkles.

A multi-peptide eye-serum study reported appearance benefits, but could not identify this peptide’s individual contribution. Most ingredient-specific efficacy claims come from supplier in-use panels. An independent review describes poor penetration of collagen-fragment peptides as a performance limitation. No independent human trial of this ingredient alone is identified in the available research.

It is generally considered to have low irritation potential at cosmetic levels. A patch test is reasonable for reactive or sensitive skin, since individual responses and finished formulas vary.